Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Clinical and therapeutic relevance of PIM1 kinase in gastric cancer.

Yan B, Yau EX, Samanta S, Ong CW, Yong KJ, Ng LK, Bhattacharya B, Lim KH, Soong R, Yeoh KG, Deng N, Tan P, Lam Y, Salto-Tellez M; Singapore Gastric Cancer Consortium.

Gastric Cancer. 2012 Apr;15(2):188-97. doi: 10.1007/s10120-011-0097-2. Epub 2011 Oct 13.


Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.

Kim J, Roh M, Abdulkadir SA.

BMC Cancer. 2010 Jun 1;10:248. doi: 10.1186/1471-2407-10-248.


Downregulation of microRNA‑33a promotes cyclin‑dependent kinase 6, cyclin D1 and PIM1 expression and gastric cancer cell proliferation.

Wang Y, Zhou X, Shan B, Han J, Wang F, Fan X, Lv Y, Chang L, Liu W.

Mol Med Rep. 2015 Nov;12(5):6491-500. doi: 10.3892/mmr.2015.4296. Epub 2015 Sep 7.


Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.

Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ, Logan SK.

Oncogene. 2013 Aug 22;32(34):3992-4000. doi: 10.1038/onc.2012.412. Epub 2012 Sep 17.


Why target PIM1 for cancer diagnosis and treatment?

Magnuson NS, Wang Z, Ding G, Reeves R.

Future Oncol. 2010 Sep;6(9):1461-78. doi: 10.2217/fon.10.106. Review.


PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2016 Nov;22(11):1303-1313. doi: 10.1038/nm.4198. Epub 2016 Oct 24. Erratum in: Nat Med. 2017 Jun 6;23 (6):788. Nat Med. 2017 Apr 7;23 (4):526.


PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma.

Leung CO, Wong CC, Fan DN, Kai AK, Tung EK, Xu IM, Ng IO, Lo RC.

Oncotarget. 2015 May 10;6(13):10880-92.


Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.

Herzog S, Fink MA, Weitmann K, Friedel C, Hadlich S, Langner S, Kindermann K, Holm T, Böhm A, Eskilsson E, Miletic H, Hildner M, Fritsch M, Vogelgesang S, Havemann C, Ritter CA, Meyer zu Schwabedissen HE, Rauch B, Hoffmann W, Kroemer HK, Schroeder H, Bien-Möller S.

Neuro Oncol. 2015 Feb;17(2):223-42. doi: 10.1093/neuonc/nou216. Epub 2014 Aug 25.


Clinical and biological significance of PIM1 kinase in osteosarcoma.

Liao Y, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

J Orthop Res. 2016 Jul;34(7):1185-94. doi: 10.1002/jor.23134. Epub 2015 Dec 31.


Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.

Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC.

PLoS One. 2012;7(7):e40364. doi: 10.1371/journal.pone.0040364. Epub 2012 Jul 13.


The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR.

Oncogene. 2016 May;35(19):2529-41. doi: 10.1038/onc.2015.325. Epub 2015 Sep 21.


Pim1 regulates androgen-dependent survival signaling in prostate cancer cells.

van der Poel HG, Zevenhoven J, Bergman AM.

Urol Int. 2010;84(2):212-20. doi: 10.1159/000277601. Epub 2010 Mar 4.


RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.

van der Meer R, Song HY, Park SH, Abdulkadir SA, Roh M.

Clin Cancer Res. 2014 Jun 15;20(12):3211-21. doi: 10.1158/1078-0432.CCR-13-3116. Epub 2014 Apr 25.


ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.

Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, Gariboldi M, Gambacorti-Passerini C.

PLoS One. 2011;6(11):e28162. doi: 10.1371/journal.pone.0028162. Epub 2011 Nov 30.


C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.

Wang L, Yin J, Wang X, Shao M, Duan F, Wu W, Peng P, Jin J, Tang Y, Ruan Y, Sun Y, Gu J.

Gastroenterology. 2016 May;150(5):1183-1195.e16. doi: 10.1053/j.gastro.2016.01.034. Epub 2016 Feb 6.


Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.

Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO.

Oncol Rep. 2011 Jun;25(6):1517-24. doi: 10.3892/or.2011.1219. Epub 2011 Mar 18.


Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.

Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, Knapp S, Duyster J, Schwaller J.

J Exp Med. 2009 Aug 31;206(9):1957-70. doi: 10.1084/jem.20082074. Epub 2009 Aug 17.


Odd-skipped related 1 is a novel tumour suppressor gene and a potential prognostic biomarker in gastric cancer.

Otani K, Dong Y, Li X, Lu J, Zhang N, Xu L, Go MY, Ng EK, Arakawa T, Chan FK, Sung JJ, Yu J.

J Pathol. 2014 Nov;234(3):302-15. doi: 10.1002/path.4391. Epub 2014 Aug 28.


Identification of IL11RA and MELK amplification in gastric cancer by comprehensive genomic profiling of gastric cancer cell lines.

Calcagno DQ, Takeno SS, Gigek CO, Leal MF, Wisnieski F, Chen ES, Araújo TM, Lima EM, Melaragno MI, Demachki S, Assumpção PP, Burbano RR, Smith MC.

World J Gastroenterol. 2016 Nov 21;22(43):9506-9514.


Decreased expression of transcription elongation factor A-like 7 is associated with gastric adenocarcinoma prognosis.

Huang CY, Chen YM, Zhao JJ, Chen YB, Jiang SS, Yan SM, Zhao BW, Pan K, Wang DD, Lv L, Li YF, Wang W, Zhou ZW, Xia JC.

PLoS One. 2013;8(1):e54671. doi: 10.1371/journal.pone.0054671. Epub 2013 Jan 25.

Supplemental Content

Support Center